Latest Headlines

31. PHC Corporation Of North America Launches TwinGuard ECO 703VXH Freezer, Bringing New Energy Efficiency To Research Sample Protection 1/15/2026

    PHC Corporation of North America (PHCNA), provider of PHCbi brand sample storage and cell cultivation solutions in North America and Latin America, a subsidiary of PHC Holdings Corporation, has launched its latest innovation in ultra-low temperature (ULT) storage: the TwinGuard ECO 703VXH.

32. Henry Schein Enters Exclusive Distribution Agreement For CytoChip's CLIA-Waived Hematology Analyzer 1/15/2026

    Henry Schein, Inc has entered into a new exclusive distribution agreement with CytoChip Inc. for its flagship product, the CitoCBC system, a U.S. Food and Drug Administration (FDA) 510(k)-cleared device.

33. Affidea Acquires A Majority Stake In LabPoint From Lindenhofgruppe, Strengthening Its Diagnostics And Laboratory Medicine Capabilities 1/14/2026

    Affidea Group, Europe’s leading provider of advanced diagnostics, community-based polyclinics and specialised healthcare services including oncology, announces the acquisition of a majority stake in LabPoint S.A. from Lindenhofgruppe.

34. CancerIQ Unveils A Risk-Based Early Cancer Detection Program For Imaging & Diagnostics 1/13/2026

    CancerIQ, the leading precision health company focused on cancer early detection, today announced a new risk-based early cancer detection program designed to help diagnostics and imaging companies — and the providers who use their technologies — match the right people to the right screening approaches and get those tests completed at scale.

35. Labcorp Expands MRD Testing For Breast, Lung And Colon Cancer Recurrence Risk 1/13/2026

    Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the continued expansion of its molecular residual disease (MRD)i portfolio designed to help clinicians detect cancer recurrence earlier than traditional imaging. 

36. HCAP Partners Announces Follow-On Acquisition For Integrated Diagnostic Services (IDS) With The Addition Of Core Analytics Lab & Radiology 1/13/2026

    HCAP Partners, a California-based private equity firm and nationally recognized impact investor, today announced a follow-on acquisition for its Integrated Diagnostic Services (IDS) platform with the addition of Core Analytics Lab & Radiology (Core), a leading provider of mobile radiology and laboratory services across California.

37. Synthego Announces Entry Into Molecular Biology And Clinical Diagnostic Reagents Market 1/13/2026

    Synthego, a recognized leader in CRISPR solutions, announces its formal entry into the molecular and clinical diagnostic reagents sector. Building upon its reputation for rigorous quality, custom manufacturing, and innovation, Synthego's significant expansion of its product portfolio empowers researchers, clinicians, and diagnostic laboratories with high-quality, reliable reagents designed to accelerate the development and deployment of cutting-edge diagnostic tests.

38. Freenome Announces Expanded Artificial Intelligence And Deep Learning Initiatives Accelerated By NVIDIA, To Advance Personalized Multi-Cancer Detection 1/12/2026

    Freenome today announced an initiative to advance its blood-based early cancer screening program by leveraging NVIDIA deep learning technology and expertise to improve the recognition of cancer-specific patterns in the blood at the disease’s earliest stages.

39. Alamar Biosciences Announces Launch Of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection In Alzheimer's Disease Research 1/12/2026

    Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, is proud to announce the launch of its Research Use Only (RUO) NULISAqpcr™ AD 5-plex Assay.

40. 10x Genomics To Advance Research In Diagnostic Applications Of Tumor Single Cell And Spatial Profiling 1/12/2026

    10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced a collaboration with Dana-Farber Cancer Institute to analyze tumor samples from patients with major solid cancer types to uncover biological features associated with treatment response, resistance and disease progression.